Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 12;146(8):1923–1932. doi: 10.1007/s00432-020-03241-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Kaplan–Meier estimates of THRα expression, THRα1 expression and THRα2 expression were analyzed. In the clear cell subtype, patients with a high nuclear expression of THRα showed a significantly reduced overall survival compared with patients with a low nuclear expression (a). In addition, high nuclear THRα1 expression was associated with significantly better overall survival in all ovarian cancer subtypes compared to patients with a low nuclear THRα1 expression (b). Patients with high THRα1 expression in the cytoplasm and mucinous subtype had a significantly decreased overall survival compared with those mucinous carcinoma patients with low cytoplasmic expression (c). High cytoplasmic THRα2 expression was associated with a significantly reduced overall survival in all ovarian cancer subtypes compared to patients with a low cytoplasmic THRα2 expression (d). In the serous subtype, patients with a high nuclear expression of THRα2 showed a significantly better overall survival compared with patients with a low nuclear expression (e). Finally, in the clear cell subtype, patients with a high nuclear expression of THRα showed a significantly reduced very low overall survival (all patients deceased within two years) compared to patients with a low nuclear expression (f)